- John Reed on J&J’s R&D model, oncology deals and pipeline expansion potentialJohn Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving him unique insight into h…Endpoints · 25d ago↗ source
- EU lobby urges member states to improve Europe’s life sciences sectorMore than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter was addressed to EU member stat…Endpoints · 25d ago↗ source
- Zymeworks CEO on why the Theravance deal is value for moneyOn the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...